Home / Resources / Exclusive Interviews / Dr. Aaron Vinik Part 6, T1 and SGLT-2s

Dr. Aaron Vinik Part 6, T1 and SGLT-2s

Dr. Aaron Vinik joins Diabetes in Control publisher Steve Freed at the AACE 2016 convention in Orlando, Florida. In Part 6 of this Exclusive Interview, Steve asks Dr. Vinik his opinion on type 1 and SGLT-s.

Aaron Vinik, MD, PhD, FCP, MACP, FACE is the Director of Research and the Neuroendocrine Unit
Murray Waitzer Endowed Chair for Diabetes Research‌ at Eastern Virginia Medical School. He is a national leader in basic and clinical neuropathy and pioneered the use of immunotherapy for autoimmune diabetic neuropathy. His research on islet regeneration and the discovery of a gene, INGAP (islet neogenesis associated protein), garnered international recognition as a potential cure for diabetes. The gene is responsible, either alone or in combination with other factors, for stimulating immature cells in the diabetic pancreas to produce insulin.

If you prefer to view the entire video, click here.

To read the transcript, click here.

To view other segments in this video:

Part 1; Bariatric Surgery Standards
Part 2: Heart Rate Variability
Part 3: The Most Important Risk Factors
Part 4: Preventing Death
Part 5: The Hesitancy to Use New Drugs
Part 6: T1 and SGLT-2s